PapersFlow Research Brief
Protein Degradation and Inhibitors
Research Guide
What is Protein Degradation and Inhibitors?
Protein degradation and inhibitors refer to strategies that target the degradation of specific proteins using small molecule inhibitors such as BET bromodomain inhibitors and PROTACs, often involving cereblon-dependent mechanisms to modulate epigenetic readers and transcriptional regulation.
This field encompasses 31,489 papers focused on targeted protein degradation through BET bromodomain inhibitors and PROTACs. Research examines histone recognition, small molecule inhibitors, and cereblon-dependent degradation for therapeutic applications in drug discovery. Growth rate over the past 5 years is not available in the data.
Topic Hierarchy
Research Sub-Topics
BET Bromodomain Inhibitors
Researchers design and test small molecules that selectively inhibit BET family bromodomains to disrupt transcriptional regulation. Studies focus on their efficacy in cancer and inflammatory diseases.
PROTAC Protein Degraders
This sub-topic develops heterobifunctional PROTACs that induce ubiquitin-mediated degradation of disease-related proteins. Researchers optimize linker design and E3 ligase recruitment for therapeutic applications.
Cereblon-Dependent Protein Degradation
Studies elucidate mechanisms of cereblon E3 ligase in small molecule-induced substrate degradation, including neosubstrate recruitment. Applications span immunomodulation and oncology.
Epigenetic Readers in Transcription
Researchers investigate how bromodomain-containing proteins recognize histone marks to regulate gene expression and super-enhancers. This includes roles in cancer cell identity and differentiation.
Histone Acetylation in Enhancers
This sub-topic analyzes H3K27ac marks distinguishing active from poised enhancers in developmental and disease states. Studies link acetylation dynamics to transcriptional output and cell fate.
Why It Matters
Protein degradation and inhibitors enable selective targeting of disease-related proteins, with BET bromodomain inhibitors disrupting epigenetic readers to alter transcriptional regulation in cancer. Filippakopoulos et al. (2010) in "Selective inhibition of BET bromodomains" demonstrated compounds that potently inhibit BET proteins, achieving IC50 values below 50 nM for BRD4, which supports applications in oncology by downregulating super-enhancers driving oncogenes like MYC, as noted in Dang (2012) "MYC on the Path to Cancer". In multiple myeloma, criteria updated by Rajkumar et al. (2014) in "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma" highlight the relevance of such degradative approaches amid 4682 citations reflecting clinical impact. Cereblon-dependent PROTACs extend this to precise protein knockdown, advancing drug discovery paradigms.
Reading Guide
Where to Start
"Selective inhibition of BET bromodomains" by Filippakopoulos et al. (2010), as it directly introduces small molecule inhibitors central to targeted degradation with clear chemical and biological validation.
Key Papers Explained
Filippakopoulos et al. (2010) "Selective inhibition of BET bromodomains" establishes potent inhibitors that Strahl and Allis (2000) "The language of covalent histone modifications" contextualizes within histone code recognition. Creyghton et al. (2010) "Histone H3K27ac separates active from poised enhancers and predicts developmental state" links acetylation marks to enhancer activity inhibited by BET blockers. Barretina et al. (2012) "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity" applies this to cancer sensitivity modeling, while Rajkumar et al. (2014) "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma" grounds it in clinical myeloma contexts.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research centers on cereblon-dependent PROTACs extending BET inhibition, with Jones et al. (1997) "Development and validation of a genetic algorithm for flexible docking" offering docking tools for degrader design. Dang (2012) "MYC on the Path to Cancer" points to MYC as a persistent target. No recent preprints available.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | The language of covalent histone modifications | 2000 | Nature | 8.5K | ✕ |
| 2 | The Cancer Cell Line Encyclopedia enables predictive modelling... | 2012 | Nature | 8.3K | ✕ |
| 3 | Development and validation of a genetic algorithm for flexible... | 1997 | Journal of Molecular B... | 6.6K | ✕ |
| 4 | International Myeloma Working Group updated criteria for the d... | 2014 | The Lancet Oncology | 4.7K | ✓ |
| 5 | Histone H3K27ac separates active from poised enhancers and pre... | 2010 | Proceedings of the Nat... | 4.3K | ✓ |
| 6 | Selective inhibition of BET bromodomains | 2010 | Nature | 4.2K | ✓ |
| 7 | An Antidiabetic Thiazolidinedione Is a High Affinity Ligand fo... | 1995 | Journal of Biological ... | 3.6K | ✓ |
| 8 | The Role of Chromatin during Transcription | 2007 | Cell | 3.5K | ✓ |
| 9 | MYC on the Path to Cancer | 2012 | Cell | 3.3K | ✓ |
| 10 | Histone deacetylases (HDACs): characterization of the classica... | 2003 | Biochemical Journal | 3.1K | ✓ |
Frequently Asked Questions
What are BET bromodomain inhibitors?
BET bromodomain inhibitors are small molecules that selectively block BET proteins involved in recognizing acetylated histones. Filippakopoulos et al. (2010) in "Selective inhibition of BET bromodomains" identified compounds with high affinity for BRD4, disrupting transcriptional regulation. These inhibitors target epigenetic readers at super-enhancers.
How do PROTACs induce protein degradation?
PROTACs recruit E3 ligases like cereblon to ubiquitinate target proteins for proteasomal degradation. This approach uses bifunctional molecules linking a protein binder to an E3 ligase ligand. The field emphasizes cereblon-dependent mechanisms in therapeutic strategies.
What role do histone modifications play in protein degradation research?
Histone modifications such as acetylation regulate chromatin structure and gene expression, influencing targets for degradation. Strahl and Allis (2000) in "The language of covalent histone modifications" established a code for these marks read by bromodomains. Creyghton et al. (2010) in "Histone H3K27ac separates active from poised enhancers and predicts developmental state" showed H3K27ac marks active enhancers.
What is the connection to cancer therapy?
Targeted degradation disrupts oncogenes via BET inhibitors and PROTACs in cancers like multiple myeloma. Barretina et al. (2012) in "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity" modeled sensitivities across 1000 lines, including to bromodomain inhibitors. Dang (2012) in "MYC on the Path to Cancer" links MYC deregulation to BET targeting.
How does cereblon contribute to degradation?
Cereblon acts as a substrate receptor in CRL4 E3 ligase complexes for PROTAC-mediated ubiquitination. This enables degradation of proteins not amenable to direct inhibition. Research highlights its role in novel drug discovery paradigms.
What is the current state of the field?
The field includes 31,489 works on targeted degradation strategies. Key papers like Filippakopoulos et al. (2010) provide foundational inhibitor chemistry. No recent preprints or news in the last 12 months are available.
Open Research Questions
- ? How can PROTAC specificity be improved for non-BET protein targets beyond cereblon-dependent systems?
- ? What are the long-term effects of BET bromodomain inhibition on super-enhancer driven transcription in normal cells?
- ? How do histone acetylation patterns predict responsiveness to protein degraders in diverse cancers?
- ? Can genetic algorithms optimize PROTAC linker designs for enhanced cereblon recruitment efficiency?
- ? What mechanisms underlie resistance to BET inhibitors in multiple myeloma models?
Recent Trends
The field maintains 31,489 papers with no specified 5-year growth rate.
Filippakopoulos et al. "Selective inhibition of BET bromodomains" (4173 citations) and Rajkumar et al. (2014) (4682 citations) remain highly cited anchors.
2010No preprints or news from the last 6-12 months reported.
Research Protein Degradation and Inhibitors with AI
PapersFlow provides specialized AI tools for Biochemistry, Genetics and Molecular Biology researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Paper Summarizer
Get structured summaries of any paper in seconds
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
See how researchers in Life Sciences use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Protein Degradation and Inhibitors with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Biochemistry, Genetics and Molecular Biology researchers